Ann Lee-Karlon

Ann Lee-Karlon is a highly accomplished executive in the biotechnology industry with extensive experience in drug development and corporate leadership. She currently serves as the CEO, President, and Board Member of EpiBiologics, a company focused on developing antibody-based protein degrader therapeutics for various applications including oncology, immunology, neuroscience, and metabolic disorders.12

Career Highlights

EpiBiologics:: Ann joined EpiBiologics as CEO in July 2023, bringing her expertise to advance the company's innovative therapeutic approaches.23

Altos Labs:: Prior to EpiBiologics, she was the Chief Operating Officer at Altos Labs from June 2021 to June 2023. At Altos, she played a crucial role in building the foundation for rapid growth, expanding the company to 500 employees across three global sites.12

Genentech:: Ann spent over 18 years at Genentech, culminating in her role as Senior Vice President. During her tenure, she:

• Led portfolio strategy and operations for Genentech Research and Early Development
• Oversaw more than 80 drug development teams
• Spearheaded major corporate partnerships and programs, including Ocrevus for multiple sclerosis and Rituxan in immunology12

Education and Achievements

Ann Lee-Karlon holds impressive academic credentials:

• PhD in Bioengineering from UC San Diego (National Science Foundation Fellow)
• MBA from Stanford University
• BS in Bioengineering from UC Berkeley12

Her achievements and contributions to the field include:

• Election as a Fellow of the American Institute for Medical and Biological Engineering
• Fellow of the inaugural class of the Health Innovators Fellowship
• Member of the Aspen Global Leadership Network
• Board member of Eko Health
• Serves on the Dean's advisory boards for UC Berkeley and UCSD schools of engineering1

Ann's leadership extends beyond her corporate roles. She has served as the president and board chair of the Genentech Patient Foundation and the Association for Women in Science.1